Akebia’s Vadadustat Lowers Hospitalization Rate 10% Versus ESA in VOICE Trial

• Akebia Therapeutics announced Oct. 26, 2026, that U.S. Renal Care presented favorable VOICE trial results at American Society of Nephrology Kidney Week.
• The 2,116-patient trial found vadadustat reduced hospitalizations versus erythropoiesis-stimulating agents, with no significant difference in mortality.
• Vadadustat recipients experienced fewer serious adverse events, more stable hemoglobin control and less need for rescue treatment.
• The trial tested three-times-weekly dosing; Vafseo, the marketed form of vadadustat, is FDA-approved for once-daily use in eligible adults receiving dialysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260920PRIMZONEFULLFEED9852976) on October 26, 2026, and is solely responsible for the information contained therein.